Medicare AdvantageDocumentationHigh impact
MA08.127g, Atezolizumab (Tecentriq®) and Atezolizumab with Hyaluronidase-tqjs (Tecentriq Hybreza™)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Aug 24, 2026
We identified it
Aug 25, 2026
Summary
MA08.127g updates medical necessity criteria for Atezolizumab (Tecentriq®) and Atezolizumab with Hyaluronidase-tqjs (Tecentriq Hybreza™) effective immediately for Medicare Advantage plans. The policy change modifies coverage requirements for these immunotherapy drugs. Billing and clinical teams must review updated medical necessity documentation requirements to ensure claims compliance.
Action Required
By August 24, 2026: Oncology and infusion center staff must review the complete MA08.127g policy text at the provided URL to identify specific medical necessity criteria changes for Atezolizumab (Tecentriq®) and Atezolizumab with Hyaluronidase-tqjs (Tecentriq Hybreza™). Update EMR templates and prior authorization workflows to reflect new criteria. Billing team must ensure all claims for these drugs include required documentation per updated medical necessity standards. Contact IBX for clarification on specific criteria if policy text is unclear. Claims submitted without updated medical necessity documentation will face denial or delay.